• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

工程化纯稳定的异源二聚体 IgA 用于开发多特异性治疗药物。

Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.

机构信息

Zymeworks Inc., Vancouver, BC, Canada.

Department of Biochemistry and Microbiology; University of Victoria, Victoria, BC, Canada.

出版信息

MAbs. 2022 Jan-Dec;14(1):2141637. doi: 10.1080/19420862.2022.2141637.

DOI:10.1080/19420862.2022.2141637
PMID:36343329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9645255/
Abstract

CE-SDS: capillary electrophoresis sodium dodecyl sulfate; DSC: differential scanning calorimetry; FACS: fluorescence-activated cell sorting; FSA: full-sized antibody; Her2: human epidermal growth factor receptor 2; MFI: mean fluorescent intensity; OAA: one-armed antibody; PBS: phosphate-buffered saline; PDB: Protein Data Bank; SEC: size-exclusion chromatography; prepSEC (preparative SEC); RMSD: root-mean-square deviation; RU: resonance units; SPR: surface plasmon resonance; TAA: tumor-associated antigen; WT: wild-type.

摘要

CE-SDS：毛细管电泳十二烷基硫酸钠；DSC：差示扫描量热法；FACS：荧光激活细胞分选；FSA：全尺寸抗体；Her2：人表皮生长因子受体 2；MFI：平均荧光强度；OAA：单臂抗体；PBS：磷酸盐缓冲盐水；PDB：蛋白质数据库；SEC：尺寸排阻色谱法；prepSEC（制备 SEC）；RMSD：均方根偏差；RU：共振单位；SPR：表面等离子体共振；TAA：肿瘤相关抗原；WT：野生型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/9bff06d617d6/KMAB_A_2141637_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/f2d5ae0bfbd5/KMAB_A_2141637_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/fa481879cebf/KMAB_A_2141637_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/f2587d6596be/KMAB_A_2141637_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/02c11dcc1da3/KMAB_A_2141637_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/9bff06d617d6/KMAB_A_2141637_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/f2d5ae0bfbd5/KMAB_A_2141637_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/fa481879cebf/KMAB_A_2141637_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/f2587d6596be/KMAB_A_2141637_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/02c11dcc1da3/KMAB_A_2141637_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9f/9645255/9bff06d617d6/KMAB_A_2141637_F0005_OC.jpg

相似文献

1
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.工程化纯稳定的异源二聚体 IgA 用于开发多特异性治疗药物。
MAbs. 2022 Jan-Dec;14(1):2141637. doi: 10.1080/19420862.2022.2141637.
2
Full-length recombinant antibodies from : production, characterization, effector function (Fc) engineering, and clinical evaluation.全长重组抗体：生产、表征、效应功能（Fc）工程和临床评估。
MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748.
3
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.TNB-738 是一种双靶向抗体，通过抑制 CD38 ecto-酶活性来提高细胞内 NAD+水平。
MAbs. 2022 Jan-Dec;14(1):2095949. doi: 10.1080/19420862.2022.2095949.
4
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.一种四价双特异性串联抗体（CD19/CD3）AFM11能够有效募集T细胞，从而有力地裂解CD19(+)肿瘤细胞。
MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.
5
Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.重新排列基于双抗体的IgG样双特异性抗体的结构域顺序可增强其抗肿瘤活性，并提高其抗降解能力和药代动力学特性。
MAbs. 2014;6(5):1243-54. doi: 10.4161/mabs.29445. Epub 2014 Oct 30.
6
Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains.具有交换抗原结合恒定结构域的Fab臂的双特异性抗体。
Biochem Biophys Rep. 2021 Feb 27;26:100959. doi: 10.1016/j.bbrep.2021.100959. eCollection 2021 Jul.
7
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.通过赋予IgG与FcαRI（CD89）结合能力来增强抗体依赖性细胞介导的细胞毒性。
MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.
8
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.用于在双特异性抗体中共同表达Fab样部分的IgG/TCR嵌合体的蛋白质设计。
MAbs. 2015;7(2):364-76. doi: 10.1080/19420862.2015.1007826.
9
End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations.用于表征和控制T细胞双特异性抗体制剂中与产品相关杂质的端到端方法。
Int J Pharm X. 2023 Jan 2;5:100157. doi: 10.1016/j.ijpx.2023.100157. eCollection 2023 Dec.
10
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.改善双特异性抗体支架的物理化学性质以提高开发可行性：通过分子设计实现质量。
MAbs. 2013 Sep-Oct;5(5):646-54. doi: 10.4161/mabs.25632. Epub 2013 Jul 8.

引用本文的文献

1
Trispecific SEED antibodies engineered for neutrophil-mediated cell killing.经工程改造用于中性粒细胞介导的细胞杀伤的三特异性SEED抗体。
MAbs. 2025 Dec;17(1):2532851. doi: 10.1080/19420862.2025.2532851. Epub 2025 Jul 15.
2
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.配备白蛋白以延长血浆半衰期的抗癌人免疫球蛋白A的工程改造。
PNAS Nexus. 2025 Feb 11;4(2):pgaf042. doi: 10.1093/pnasnexus/pgaf042. eCollection 2025 Feb.
3
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process.

本文引用的文献

1
Therapeutic exploitation of neutrophils to fight cancer.中性粒细胞治疗性应用于癌症治疗。
Semin Immunol. 2021 Oct;57:101581. doi: 10.1016/j.smim.2021.101581. Epub 2021 Dec 23.
2
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn and .人 FcRn 与白蛋白结合后，人 IgA 的白蛋白结合域融合蛋白的延长的血浆半衰期依赖于 pH。
MAbs. 2021 Jan-Dec;13(1):1893888. doi: 10.1080/19420862.2021.1893888.
3
Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.多聚免疫球蛋白受体在 IgA 和 IgM 穿越细胞转运中的作用。
能力越大，责任越大：在抗体研发过程早期广泛衡量Fc介导的效应子功能的重要性。
MAbs. 2025 Dec;17(1):2453515. doi: 10.1080/19420862.2025.2453515. Epub 2025 Jan 16.
Int J Mol Sci. 2021 Feb 25;22(5):2284. doi: 10.3390/ijms22052284.
4
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.增强型抗体抗癌疗法增强中性粒细胞的细胞毒性。
J Clin Invest. 2021 Mar 15;131(6). doi: 10.1172/JCI134680.
5
IgA transcytosis and antigen recognition govern ovarian cancer immunity.IgA 穿越和抗原识别控制卵巢癌免疫。
Nature. 2021 Mar;591(7850):464-470. doi: 10.1038/s41586-020-03144-0. Epub 2021 Feb 3.
6
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.推动IgA抗体作为治疗剂的Fc工程策略。
Antibodies (Basel). 2020 Dec 15;9(4):70. doi: 10.3390/antib9040070.
7
The structures of secretory and dimeric immunoglobulin A.分泌型和二聚体免疫球蛋白 A 的结构。
Elife. 2020 Oct 27;9:e56098. doi: 10.7554/eLife.56098.
8
When Therapeutic IgA Antibodies Might Come of Age.当治疗性 IgA 抗体走向成熟。
Pharmacology. 2021;106(1-2):9-19. doi: 10.1159/000510251. Epub 2020 Sep 18.
9
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.同种型转换将抗 CD40 拮抗作用转化为激动作用，从而引发强大的抗肿瘤活性。
Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21.
10
Structure of the secretory immunoglobulin A core.分泌型免疫球蛋白 A 核心的结构。
Science. 2020 Feb 28;367(6481):1008-1014. doi: 10.1126/science.aaz5807. Epub 2020 Feb 6.